CAS: 1421783-64-3
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
GZD824 REF: IN-DA009HG2CAS: 1421783-64-3 | 98% | To inquire | Mon 02 Dec 24 | |
Olverembatinib dimesylate REF: TM-T2429CAS: 1421783-64-3 | 100% - 99.81% | 39.00 €~463.00 € | Tue 10 Dec 24 | |
GZD 824 REF: 3D-FG104178CAS: 1421783-64-3 | Min. 95% | To inquire | Mon 13 Jan 25 |
Ref: IN-DA009HG2
5mg | 183.00 € | ||
10mg | 260.00 € | ||
25mg | 543.00 € | ||
50mg | 614.00 € | ||
100mg | To inquire |
Estimated delivery in United States, on Monday 2 Dec 2024
Olverembatinib dimesylate
CAS:1421783-64-3
Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).
Formula:
C29H27F3N6O·2CH4O3S
Purity:
100% - 99.81%
Color and Shape:
Solid
Molecular weight:
724.77
Ref: TM-T2429
1mg | 39.00 € | ||
2mg | 56.00 € | ||
5mg | 87.00 € | ||
10mg | 123.00 € | ||
25mg | 230.00 € | ||
50mg | 317.00 € | ||
100mg | 463.00 € | ||
1mL*10mM (DMSO) | 121.00 € |
Estimated delivery in United States, on Tuesday 10 Dec 2024
GZD 824
CAS:1421783-64-3
GZD 824 is a receptor molecule that competes with the receptor for the protein ubiquitin. …
Formula:
C29H27F3N6O•(CH4O3S)2
Purity:
Min. 95%
Molecular weight:
724.77 g/mol
Ref: 3D-FG104178
5mg | To inquire | ||
10mg | To inquire | ||
25mg | To inquire |
Estimated delivery in United States, on Monday 13 Jan 2025